Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants.
about
Androgen receptor variants occur frequently in castration resistant prostate cancer metastasesSplice Variants of Androgen Receptor and Prostate CancerResistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate CancerMechanisms of resistance in castration-resistant prostate cancer (CRPC)Persistent androgen receptor addiction in castration-resistant prostate cancerTargeting molecular resistance in castration-resistant prostate cancerODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancerDrug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategiesAbiraterone in prostate cancer: a new angle to an old problemAbiraterone in the treatment of metastatic castration-resistant prostate cancerBiologic and clinical significance of androgen receptor variants in castration resistant prostate cancerAndrogen receptor on the move: boarding the microtubule expressway to the nucleusBeyond T and DHT - novel steroid derivatives capable of wild type androgen receptor activationAndrogens and prostate diseaseEvolving landscape and novel treatments in metastatic castrate-resistant prostate cancerQuo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapiesInterplay between genomic alterations and androgen receptor signaling during prostate cancer development and progressionRecent progress in pharmaceutical therapies for castration-resistant prostate cancerMolecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancerAndrogen biosynthesis in castration-resistant prostate cancerFree testosterone drives cancer aggressiveness: evidence from US population studiesAR-V7 and resistance to enzalutamide and abiraterone in prostate cancerEmerging data on androgen receptor splice variants in prostate cancerHow Precisely Can Prostate Cancer Be Managed?Stilbene induced inhibition of androgen receptor dimerization: implications for AR and ARΔLBD-signalling in human prostate cancer cellsCharacterization of niphatenones that inhibit androgen receptor N-terminal domainRegistered report: androgen receptor splice variants determine taxane sensitivity in prostate cancerSuppression of LIM and SH3 Domain Protein 1 (LASP1) Negatively Regulated by Androgen Receptor Delays Castration Resistant Prostate Cancer Progression.The RNA-binding protein Sam68 regulates expression and transcription function of the androgen receptor splice variant AR-V720(S)-protopanaxadiol-aglycone downregulation of the full-length and splice variants of androgen receptor.TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer.Targeted androgen pathway suppression in localized prostate cancer: a pilot study.Androgen receptor splice variants determine taxane sensitivity in prostate cancer.The link between androgen receptor splice variants and castration-resistant prostate cancer.Androgen receptor splice variants and prostate cancer: From bench to bedside.Improving treatment strategies for patients with metastatic castrate resistant prostate cancer through personalized computational modeling.Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utilityAndrogen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy.Targeting androgen receptor action for prostate cancer treatment: does the post-receptor level provide novel opportunities?
P2860
Q21558502-75F83190-8D64-46A4-8C5C-2C6B6974487FQ26740592-6F3CF915-0BF4-4B89-83AB-9C90B05D8DDCQ26751237-2C33BF0E-7059-431B-B6D0-60EAD44A5C13Q26774221-AFB3A37F-9004-473D-810D-71257505E840Q26777163-B02F432C-364B-476A-9B02-88E6CF626717Q26795445-03C0B0C6-3048-4AA1-BBA3-E62A990AC63BQ26796568-BA69CE65-60D9-45D8-B8A6-63B9C7F0A43CQ26796704-4A67DF8D-6B3D-4419-A896-F90AF02EED17Q26828810-CBB86A63-C990-49DB-8435-8A4B6B7F12F1Q26853635-FD41BABF-689B-4987-AD59-5F2C595B2BCAQ26858922-E5599088-383A-485E-AF57-C253DDE6379FQ26862560-1248D8AD-409D-4445-ADA9-3836CCEC3F2EQ27007208-0E923F9C-5AB3-4F0C-B133-258D96BAC260Q27010093-28A06922-099A-4F51-93E5-E2BDFE6A7FFAQ27010542-B6548EF3-4EA6-4587-888A-0393744EE37EQ27011642-0831DCAD-1BD7-49A0-A0E9-A7F95B057993Q27022288-270B7F80-121A-45C4-8A9D-4BF0EB116A3DQ27022567-083BB7F8-4670-4C16-A531-F1137021154FQ27024775-60B1CB59-5ADB-4F02-97A2-94076D33541BQ27026044-40BEB6DB-8900-4670-941D-F197E8B21117Q27324026-9E67F72F-2EBF-406D-8A59-AD5C9B29294DQ27853062-03C66D1F-E45A-4301-BD0D-5E4DB66968E0Q28077830-B1C3E8A1-828B-47B3-B6AD-EA644075DC68Q28078942-2BF912D8-4AEB-4AB1-98D5-505D7D4C95C0Q28539233-1541CE79-4A8A-4603-8342-2654387C76B8Q28543404-3DA1766B-3B31-4882-8B8F-AD1A94022E68Q28607383-7ADD6E6B-FA78-42FA-AF5B-3B17C236442EQ30008838-B72FD162-83F7-44CF-8049-BCE4B3981836Q30370955-B0AEA146-1AD7-47F6-BDBA-42D122711F57Q30528764-709E8587-EEF5-4FAA-AEBF-B1FD781ACD15Q30554439-8C7E6437-1DC1-4399-9589-F45A33013CDCQ30563985-3295690D-64FC-4A55-AC17-035110EC1B95Q30577613-D011684E-C64D-4C03-A368-78F11AE6FF67Q30618562-AC16DDD3-3F1F-4749-A1F8-06CE7EE935DAQ33567024-5FBB1ABB-178F-4FE2-A4A8-E89EDBEBF9E3Q33589156-E08CF483-C83E-4176-8A05-5EA67075B053Q33621403-D8776F09-D578-46B7-A80D-92D42B53BF5CQ33656820-660E28DC-2606-4375-B54A-0F37995611EFQ33688956-D20D1494-8049-4265-BCFE-ED1B14BC0D59Q33775717-42A131F4-931C-4172-B872-DA73F03D16F2
P2860
Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Resistance to CYP17A1 inhibiti ...... ogen receptor splice variants.
@ast
Resistance to CYP17A1 inhibiti ...... ogen receptor splice variants.
@en
type
label
Resistance to CYP17A1 inhibiti ...... ogen receptor splice variants.
@ast
Resistance to CYP17A1 inhibiti ...... ogen receptor splice variants.
@en
prefLabel
Resistance to CYP17A1 inhibiti ...... ogen receptor splice variants.
@ast
Resistance to CYP17A1 inhibiti ...... ogen receptor splice variants.
@en
P2093
P2860
P1476
Resistance to CYP17A1 inhibiti ...... ogen receptor splice variants.
@en
P2093
Alvin M Matsumoto
Brett T Marck
Elahe A Mostaghel
Peter S Nelson
R Bruce Montgomery
Robert L Vessella
Stephen Balk
Stephen R Plymate
P2860
P304
P356
10.1158/1078-0432.CCR-11-0728
P407
P577
2011-08-01T00:00:00Z